Search - tctmd.com

Displaying 181 - 200 of 200

Sort: Relevancy | Date

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

L.A. McKeown

January 30, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

Michael O'Riordan

November 11, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

March 09, 2013

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

Advertisement

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content